share_log

Redhill Biopharma shares are trading lower after the company announced preliminary top-line data from the Phase 2/3 study with opaganib showed that the study did not meet its primary endpoint.

Benzinga ·  Sep 14, 2021 09:07
Redhill Biopharma shares are trading lower after the company announced preliminary top-line data from the Phase 2/3 study with opaganib showed that the study did not meet its primary endpoint.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment